Leap Therapeutics Secures $59 Million Investment for Crypto Acquisition
- Leap Therapeutics raised $59 million through a private placement, with shares and warrants priced at $0.61439 per unit.
- Winklevoss Capital, founded by Cameron and Tyler Winklevoss, will receive two board seats as part of the investment.
- A portion of the funds will be allocated to purchasing cryptocurrency to hold on its balance sheet.
- The remaining capital will support the clinical development of Leap’s immuno-oncology therapies.
- This move positions Leap among public companies integrating crypto into their treasury reserves.
The investment highlights a trend where public companies are increasingly adopting cryptocurrency as part of their financial strategy. Leap plans to disclose more about its digital asset strategy in the future.
With this $59 million investment, Leap Therapeutics aims to enhance its portfolio by incorporating cryptocurrency while advancing its drug candidates in immuno-oncology.(Source)
